Aligos Therapeutics, Inc. (ALGS) is seeing an uptick in its stock price today, likely driven by recent developments in treatments for Alagille Syndrome (ALGS). Ipsen has announced the launch of KAYFANDA® (odevixibat), a new treatment for cholestatic pruritus in patients with ALGS aged six months or older. This drug is the first ileal bile acid transporter inhibitor (IBATi) to be tested in a robust Phase III clinical trial program for ALGS, showing significant reductions in pruritus and serum bile acids, as well as improvements in sleep independent of pruritus. The introduction of KAYFANDA could potentially enhance treatment options for patients, thereby influencing investor sentiment positively.
The current price of Aligos Therapeutics' stock is $39.67, reflecting a 3.44% increase from the previous close of $38.35. The stock has experienced a high of $39.91 and a low of $36.37 so far today, with a trading volume of 217,928 shares, which is 63.25% of its average daily volume of 344,561.